Q1 2025 IRadimed Corp Earnings Call Transcript
Key Points
- iRadimed Corp (IRMD) reported its 15th consecutive quarter of record revenues, achieving $19.5 million in Q1 2025, an 11% increase over the same period last year.
- Gross profit remained strong at 76.1%, with GAAP diluted earnings per share increasing by 16% from Q1 2024.
- The company experienced a 16% growth in IV and fusion pump systems revenue and a 23% increase in disposable revenue.
- Domestic sales accounted for 82% of total revenue, increasing by 19% to $16 million.
- The company is on track with its new facility, expecting full operations by the end of July 2025, mitigating potential material cost impacts effectively.
- International sales declined by 15% to $3.5 million, indicating challenges in global market expansion.
- Operating expenses increased to $9.4 million, driven by higher general and administrative costs, including legal and professional fees.
- Research and development expenses decreased by 24%, which may impact future innovation and product development.
- Free cash flow decreased significantly due to $3.9 million in capital expenditures, primarily for the new facility.
- The impact of tariffs remains uncertain, with potential indirect effects on supplier pricing and cost structures.
Welcome to the IRADIMED Corporation first-quarter of 2025 financial results conference call. (Operator Instructions) This call is being recorded today, Monday, May 5, 2025, and contains time-sensitive accurate information only today. Earlier, IRADIMED released its financial results for the first quarter of 2025. A copy of this press release announcing the company's earnings is available under the heading News on their website at IRADIMED.com. A copy of the press release was also furnished to the Securities and Exchange Commission on Form 8-K and can be found at sec.gov.
This call is being broadcast live over the Internet on the company's website at IRADIMED.com, and a replay will be available on the website for the next 90 days. Some of the information in today's session will constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements focus on future performance, results, plans and events and may include the company's expected future results. [It] reminds you that future results may differ materially from these
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
